I
Ivantis
Researching Innovative Solutions for Glaucoma
About Ivantis
Ivantis Inc. specializes in developing innovative medical devices for the treatment of glaucoma, specifically targeting patients undergoing cataract surgery. The company's flagship product, the Hydrus Microstent, is a minimally invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure in patients with mild to moderate primary open-angle glaucoma. By integrating this device during cataract surgery, Ivantis aims to improve patient outcomes by reducing or eliminating the need for glaucoma medications. The company operates in the ophthalmology market, serving healthcare providers and patients across the United States, United Kingdom, Canada, Australia, and Singapore. Ivantis generates revenue through the sale of its Hydrus Microstent to medical institutions and eye care professionals. The business model focuses on leveraging clinical trial data to demonstrate the efficacy and safety of its products, thereby driving adoption among ophthalmologists and surgeons.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Frankfurt, Germany
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 27.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Surgery, Glaucoma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2021 | $475M | $475M | Alcon | — |
| SERIES COther financing | Jan 2017 | $25M | $100M | NEA · RA Capital Management | — |
Growth signals
Latest recorded traffic for Ivantis is 170 monthly website visits, down 94.5% over the last three months. Ivantis's team declined 99.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Ascension Ventures
EDBI
NEA
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
Alcon
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ivantis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ivantis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.